KANSAS CITY, Mo., Oct. 27 /PRNewswire/ -- Thomas Reidy, an investor in Trinity Biotech plc (Nasdaq: TRIB), an Ireland-based developer and manufacturer of diagnostic products whose American Depository Receipts are traded on NASDAQ, will host an investor conference call November 3, 2008, at 10:00am EST, to discuss the recent shareholder proposal calling for the removal and replacement of Trinity Biotech's current directors.
On October 16, 2008, Mr. Reidy, and nine other shareholders, sent a
letter to Trinity Biotech requesting that a special meeting of shareholders
be held to consider the immediate removal of the current directors of
Trinity Biotech. In the same letter, the investor group, who collectively
hold beneficial ownership of more than 10% of Trinity Biotech's voting
stock, directed that Trinity Biotech shareholders be given the opportunity
to vote on the following slate of replacement directors:
-- Dr. Jack C. Chow, M.D., M.B.A. -- Partner, CRV Capital, LLC and adjunct
professor at Carnegie Mellon University's Heinz School of Public Policy
-- Mr. Mike Gausling -- Managing Partner, Originate Ventures;
-- Dr. John H. Halsey, Ph.D. -- Chief Executive Officer, Director,
Founder, ProGene Biomedical, Inc. (dba IBT Laboratories);
-- Mr. Steven A. Mock, CPA -- Partner, BKD, LLP;
-- Mr. Thomas Reidy; and
-- Mr. Clint Severson -- Chairman, President and CEO of Abaxis, Inc.
According to Irish Law, Trinity Biotech must call a special meeting of shareholders, called an Extraordinary General Meeting, if the meeting is requested by shareholders holding in excess of 10% of the voting paid-up capital of the company.
The purpose of the confer
|SOURCE Thomas J. Reidy, Kansas City|
Copyright©2008 PR Newswire.
All rights reserved